Article
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
Proceedings of the National Academy of Sciences of the United States of America - 1 Jun 2010
Loi Sherene, Haibe-Kains Benjamin, Majjaj Samira, Lallemand Francoise, Durbecq Virginie, Larsimont Denis, Gonzalez-Angulo Ana M, Pusztai Lajos, Symmans W Fraser, Bardelli Alberto, Ellis Paul, Tutt Andrew N J, Gillett Cheryl E, Hennessy Bryan T, Mills Gordon B, Phillips Wayne A, Piccart Martine J, Speed Terence P, McArthur Grant A, Sotiriou Christos
Abstract excerpt
PIK3CA mutations are reported to be present in approximately 25% of breast cancer (BC), particularly the estrogen receptor-positive (ER+) and HER2-overexpressing (HER2+) subtypes, making them one of the most common genetic aberrations in BC. In experimental models, these mutations have been shown to activate AKT and induce oncogenic transformation, and hence these lesions have been hypothesized to render tumors...
Topics
- Antibiotics, Antineoplastic
- Antineoplastic Agents, Hormonal
- Base Sequence
- Breast Neoplasms
- Cell Line, Tumor
- Class I Phosphatidylinositol 3-Kinases
- DNA Primers